A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

NCT01585233 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: ASKP1240
DRUG: Placebo

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]